$SNTI News

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data

Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026; Upon Effectiveness Of Holding Company Reorganization, Senti Biosciences Holdings Would Become Successor Issuer To Co

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

Senti Biosciences Publishes New Peer-Reviewed Research In Cell Systems Demonstrating Its Systematic Framework For Engineering NOT-Gated Chimeric Antigen Receptor Circuits In Both T Cells And Natural Killer Cells

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Evaluating SENTI-202, CD33/FLT3-Targeting Logic Gated CAR NK Cell Therapy, In Patients With R/R AML

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026